Clinical Trial Update: Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating how hepatic impairment affects Olverembatinib exposure, to inform dosing in patients with liver dysfunction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Pharmacokinetic, Olverembatinib | Phase 1 | Status: RECRUITING